chufangao/CTO huggingface dataset:
Clinical trial NCT02699723: Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer
Official title: Oral Arsenic Trioxide and Itraconazole for the Treatment of Patients With Advanced Basal Cell Carcinoma
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Logistics
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-31
Primary completion date: 2021-09-30
Completion date: 2021-09-30
Plan to share individual participant data: NO
Clinical trial NCT03412747: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Official title: A Phase 3, Multicenter, Randomized, Double-Blind Study With an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Acronym: BE SURE
Sponsor: UCB Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 478.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-01-26
Primary completion date: 2019-02-07
Completion date: 2020-02-26
Baseline population: Baseline Characteristics refer to the Randomized Set (RS) which consisted of all randomized study participants.
Plan to share individual participant data: YES
IPD sharing description: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Clinical trial NCT04700046: Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2
Official title: A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of Mexiletine During 26 Weeks of Treatment in Patients With Myotonic Dystrophy Type 1 and Type 2 [The MIND Study]
Acronym: MIND
Sponsor: Lupin Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Assessing novel alternative study designs and regulatory pathways
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-03
Primary completion date: 2024-07-01
Completion date: 2024-08-12
Clinical trial NCT04390503: Convalescent Plasma for Early Treatment of COVID-19
Official title: A Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Plasma for Early Treatment of COVID-19
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Enrollment challenges
Enrollment: 223.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-12
Primary completion date: 2022-01-06
Completion date: 2022-01-06
Plan to share individual participant data: NO
Clinical trial NCT05559476: A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above
Official title: A Phase 3, Open-label, Randomized, Controlled, Multicountry Study to Evaluate the Immune Response, Safety and Reactogenicity of RSVPreF3 OA Investigational Vaccine When Co-administered With FLU HD Vaccine in Adults Aged 65 Years and Above
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1029.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-20
Primary completion date: 2023-03-07
Completion date: 2023-08-15
Plan to share individual participant data: YES
IPD sharing description: GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
IPD time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Clinical trial NCT04451174: Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia
Official title: Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia (PREDCOVID)
Acronym: PREDCOVID
Sponsor: University of Chile (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Corticosteroid use approval
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-23
Primary completion date: 2021-01-30
Completion date: 2021-01-30
Plan to share individual participant data: YES
IPD time frame: starting 6 months after publication
Clinical trial NCT04547985: Naltrexone Treatment for Prolonged Grief Disorder (PGD)
Official title: Naltrexone Treatment for Prolonged Grief Disorder: A Pilot Study
Acronym: PGD
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: We are terminating the study due to low accrual.
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-05
Primary completion date: 2023-10-16
Completion date: 2023-10-16
Limitations and caveats: Due to low accrual, only descriptive statistics are presented.
Plan to share individual participant data: NO
Clinical trial NCT02920008: Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Official title: A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Previously Treated Acute Myeloid Leukemia
Sponsor: Astex Pharmaceuticals, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 302.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-03-16
Primary completion date: 2020-01-20
Completion date: 2020-06-01
Plan to share individual participant data: NO
Clinical trial NCT05059873: Treatment Efficacy of Systemic Corticosteroids in AECOPD Patients With Higher Blood Eosinophil Levels
Official title: A Multicenter Double-blind Randomized Controlled Trial of Systemic Corticosteroid Therapy in AECOPD Patients Admitted to Hospital With Higher Blood Eosinophil Levels
Sponsor: Capital Medical University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Difficulty in recruiting subjects
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-03-05
Primary completion date: 2024-04-30
Completion date: 2024-05-31
Plan to share individual participant data: YES
IPD sharing description: Data about individual deidentified participants of this trial will be available from the corresponding author Zhaohui Tong (Email: tongzhaohuicy@sina.com) on reasonable request after the main results of the ECHO study have been published
IPD time frame: After the main results of the ECHO study have been published
IPD access criteria: Supporting information will be available from the corresponding author Zhaohui Tong (Email: tongzhaohuicy@sina.com)
Clinical trial NCT03693612: GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
Official title: A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 26.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-26
Primary completion date: 2021-06-25
Completion date: 2021-09-16
Baseline population: The sponsor made the decision to not continue the study at the end of Part 1 based on the totality of available data due to lack of efficacy and not due to safety. Hence Part 2 was not initiated and participants were not enrolled.
Limitations and caveats: The sponsor made the decision to not continue the study at the end of Part 1 based on the totality of available data due to lack of efficacy and not due to safety. Hence Part 2 was not initiated and participants were not enrolled in the same.
Plan to share individual participant data: YES
IPD sharing description: GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
IPD time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Clinical trial NCT04482686: Trial of Combination Therapy to Treat COVID-19 Infection
Official title: A Phase I Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infection
Sponsor: ProgenaBiome (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 31.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-09
Primary completion date: 2022-05-15
Completion date: 2022-07-15
Plan to share individual participant data: NO
Clinical trial NCT04809649: SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole
Official title: SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole
Acronym: SITRIS
Sponsor: University of California, Davis (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor is not proceeding with study due to budget cuts as a result of COVID-19.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-15
Primary completion date: 2022-09-30
Completion date: 2022-09-30
Plan to share individual participant data: NO
Clinical trial NCT04436471: An Open Study of the Safety, Tolerability and Immunogenicity of the Drug Gam-COVID-Vac Vaccine Against COVID-19
Official title: An Open Study of the Safety, Tolerability and Immunogenicity of the Drug Gam-COVID-Vac a Solution for Intramuscular Injection With the Participation of Healthy Volunteers
Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 38.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-06-17
Primary completion date: 2020-08-03
Completion date: 2020-08-10
Plan to share individual participant data: NO
Clinical trial NCT03187210: Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas
Official title: Brentuximab Vedotin and BeEAM High-dose Chemotherapy (B-BeEAM) With Autologous Stem Cell Transplantation for CD30+ Lymphomas, a Phase I/II Study
Acronym: BAL
Sponsor: Insel Gruppe AG, University Hospital Bern (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: SUSPENDED 
Why stopped: low accrual
Enrollment: 20.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-09-01
Primary completion date: 2023-11-02
Completion date: 2024-11-30
Plan to share individual participant data: YES
Clinical trial NCT05180318: Prophylactic Effects of Esketamine in Surgical Patients
Official title: Effects of Esketamine Pre-administration on Blood Lymphocyte Subsets and Inflammatory Factors in Early Postoperative Period:
Sponsor: Wuhan Union Hospital, China (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: No Participants Enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-10-01
Primary completion date: 2024-11-30
Completion date: 2024-12-31
Plan to share individual participant data: YES
IPD sharing description: After publication, the data supporting the findings of this study can be provided by the corresponding author upon reasonable request. Participant data without names and identifiers can be provided by the corresponding author and the Wuhan Union Hospital after approval. The research team will provide an email address for communication purposes once approval is obtained regarding sharing the data with others. The proposal with detailed description of the study objectives and statistical analysis plan will be needed for evaluation of the purpose for the data request. Additional materials may also be required during the process of evaluation.
IPD time frame: Six months after publication.
IPD access criteria: Upon reasonable request.
Clinical trial NCT03963232: A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine
Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Galcanezumab in Patients With Episodic Migraine-the Persist Study
Acronym: PERSIST
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 520.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-30
Primary completion date: 2021-07-27
Completion date: 2022-03-11
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03977675: The Role of HNKs in the Antidepressant Effect of Ketamine
Official title: The Role of HNKs in the Antidepressant Effect of Ketamine
Sponsor: Columbia University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: PI left the institution
Enrollment: 8.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-05-15
Primary completion date: 2020-07-02
Completion date: 2020-07-02
Plan to share individual participant data: NO
Clinical trial NCT04059757: Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute GVHD
Official title: Fecal Microbiota Transplantation For The Treatment Of Gastro-Intestinal Acute Graft Versus Host Disease
Sponsor: Case Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Drugs unavailable
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-05-31
Primary completion date: 2023-06-30
Completion date: 2023-09-30
Plan to share individual participant data: YES
IPD sharing description: Individual participant data that underline or influence the results observed from the study.
IPD time frame: Beginning 3 months and ending 5 years following article publication
IPD access criteria: Investigators who provide a methodologically sound proposal for use of requested data.
Clinical trial NCT02975570: Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin
Official title: Prospective, Randomized, Open Label Phase 3 Study of the Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin for Treatment of Patients With Fluoroquinolone-susceptible Multidrugresistant--Tuberculosis (MDR-TB)
Acronym: DAZZLE
Sponsor: Boston University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The study could not be conducted since funding was not obtained.
Enrollment: 0.0 (ACTUAL)
Number of arms: 6.0
Start date: 2017-08-31
Primary completion date: 2021-08-31
Completion date: 2022-08-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04905563: NSAIDs vs Opioids for Post-op Pain in Supracondylar Humerus Fractures
Official title: Post-operative Pain Management in Supracondylar Humerus Fractures: A Randomized, Double-blinded, Prospective Study
Sponsor: Le Bonheur Children's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Clinical evidence supporting the hypothesis of this study has been published
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-07
Primary completion date: 2024-01-05
Completion date: 2024-01-05
Plan to share individual participant data: NO
IPD sharing description: No Plan has been made for such data sharing
Clinical trial NCT03628391: Haloperidol for Delirium in Adult Critically Ill Patients
Official title: Efficacy of Haloperidol to Decrease the Burden of Delirium in Adult Critically Ill Patients (EuRIDICE): a Prospective Randomised Multi-center Double-blind Placebo-controlled Clinical Trial
Acronym: EuRIDICE
Sponsor: Erasmus Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was stopped because of futility of being able to reach a one-day difference between treatment groups in the primary outcome of DCFD in the intended sample size.
Enrollment: 142.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-22
Primary completion date: 2020-02-03
Completion date: 2021-01-23
Plan to share individual participant data: UNDECIDED
IPD sharing description: Can be retrieved after contacting the principal investigator
Clinical trial NCT00075946: Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Official title: Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens For Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
Sponsor: Eastern Cooperative Oncology Group (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 545.0 (ACTUAL)
Number of arms: 2.0
Start date: 2004-01-23
Primary completion date: 2013-09-30
Completion date: 2021-08-31
Baseline population: As the primary analysis only includes randomized patients, the baseline characteristics were provided among patients who were correctly randomized to one of the two arms for maintenance therapy.
Clinical trial NCT04863248: Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)
Official title: A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
Acronym: PRESERVE 4
Sponsor: G1 Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Treatment paradigm in second- and third-line NSCLC is shifting away from docetaxel, the backbone chemotherapy therapy used in this study.
Enrollment: 10.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-30
Primary completion date: 2022-02-02
Completion date: 2022-02-02
Limitations and caveats: This study was terminated earlier than initially proposed by the Sponsor for non-safety related reasons; only 7 patients were randomized and treated. Therefore, only limited safety summary tables were generated, and no efficacy analyses were conducted.
Clinical trial NCT02092324: Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Official title: Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R
Sponsor: OHSU Knight Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 51.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-07-08
Primary completion date: 2019-11-22
Completion date: 2020-01-24
Clinical trial NCT03526861: Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).
Official title: A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial to Evaluate the Efficacy, Safety, and Tolerability of Tralokinumab Monotherapy in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) Who Are Candidates for Systemic Therapy
Sponsor: LEO Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 301.0 (ACTUAL)
Number of arms: 8.0
Start date: 2018-06-19
Primary completion date: 2020-04-15
Completion date: 2021-03-16
Plan to share individual participant data: YES
IPD access criteria: De-identified Individual Participant Data can be made available to researchers and is subject to approved scientifically sound research proposal and signed data-sharing agreement.
Clinical trial NCT03852472: Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)
Official title: A Randomized , Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa
Sponsor: ChemoCentryx (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 435.0 (ACTUAL)
Number of arms: 5.0
Start date: 2018-12-21
Primary completion date: 2021-01-14
Completion date: 2021-03-09
Plan to share individual participant data: NO
Clinical trial NCT05077085: Bezlotoxumab Versus FMT for Multiple Recurrent CDI
Official title: New Treatment Strategy for Patients With Multiple Recurrent Clostridioides Difficile Infection With Bezlotoxumab as First Option
Acronym: BSTEP
Sponsor: Leiden University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Withdrawn
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-31
Primary completion date: 2024-07-31
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT03539900: Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder
Official title: Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 89.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-17
Primary completion date: 2022-04-19
Completion date: 2023-03-22